Memorial Sloan Kettering Cancer Center Psychopharmacology in Cancer Care 2024

60 $

+ Include: 11 videos + 14 pdfs, size: 7.93 GB

+ Target Audience: Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians

Description

+ Include: 11 videos + 14 pdfs, size: 7.93 GB

+ Target Audience: Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians

+ Sample video: contact me for sample video

+ Information:

Date & Location

Saturday, April 6, 2024, 8:30 AM – 5:30 PM, Online, New York, NY

Specialties
Specialties – Behavioral Care, Critical Care, General and Family Practice, Geriatric Medicine, Hematology, Integrative Medicine, Internal Medicine, Medical Oncology, Neurology, Nurse Anesthetist, Nurse Practitioner, Nursing, Pain Medicine, Psychiatry, Psychology, Social Work
Overview

Clinicians have numerous tools at their disposal to help adult cancer patients deal with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however, psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology. Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses, and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.

This course is designed for the non-prescribing psycho-oncology clinician as well as the psychiatrist who is new to the world of Psycho-pharmaco-oncology. Oncologists, palliative care clinicians, advanced practice nurses, and oncology nurses will find this course useful as well. Expert faculty will focus on key target disorders and symptoms amenable to psychopharmacological intervention, including anxiety, depression, delirium, sleep disturbance, pain, fatigue, and weight and appetite loss. The course will also include updates on COVID-19-related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain. The role of clinical social work in psychosocial support will also be reviewed. Participants will learn to identify psychological reactions to medical conditions or treatments; psychiatric presentations of medical conditions or treatments; medical presentations of psychiatric conditions and common medical complications of psychiatric conditions or treatments.

Basic information will be presented about medications used to alleviate Quality of Life symptoms that arise in the cancer setting from diagnosis to survivorship or end-of-life care, and the interface of psychotherapy and medication management. We will review why certain medications are used and why some are avoided, looking at potential benefits, unwanted side effects, and drug-drug interactions, since you may be the first person to identify a serious adverse event. The course will also enhance your ability to provide psychoeducation to patients regarding psychiatric medications.

This educational program is co-sponsored by the MSK Psycho-Oncology Education and Training Institute (POETI).

Who Should Attend

The target audience for this course includes Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians, Physician Assistants, Nurse Practitioners, Nurses, Psychologists, Social Workers and Counselors

Objectives
  1. Describe basic psycho-pharmaco-oncology principles for understanding and treating anxiety, depression and delirium in people with cancer.
  2. Discuss basic psycho-pharmaco-oncology principles for understanding and improving quality of life and psychiatric palliative care in people with cancer, including managing cognitive changes, insomnia, fatigue, poor appetite and weight loss, and pain.
  3. Identify the nuances of psycho-pharmaco-oncology related to COVID-19 related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain in people with cancer.

 

+ Topics:

Anxiety Disorders.mp4
Anxiety Disorders.pdf
Cancer and Cancer-Treatment Related Cognitive Changes.mp4
Cancer and Cancer-Treatment Related Cognitive Changes.pdf
Cancer-Related Fatigue.mp4
Cancer-Related Fatigue.pdf
Caring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.mp4
Caring for the Whole Patient- The Role of Clinical Social Work in Psychosocial Support.pdf
Delirium Handouts.pdf
Delirium.mp4
Delirium.pdf
Depressive Disorders.mp4
Depressive Disorders.pdf
Fatigue Handouts.pdf
Ketamine and Esketamine for Depression.mp4
Ketamine and Esketamine for Depression.pdf
Novel Psychopharmacologic Interventions in Oncology.mp4
Novel Psychopharmacologic Interventions in Oncology.pdf
Pain.mp4
Psychopharm2024_Brochure.pdf
Sleep Disorders.mp4
Sleep Disorders.pdf
Sleep Handout.pdf
Weight and Appetite Loss.mp4
Weight and Appetite Loss.pdf

Reviews

There are no reviews yet.

Be the first to review “Memorial Sloan Kettering Cancer Center Psychopharmacology in Cancer Care 2024”

Your email address will not be published. Required fields are marked *